Pharma firm Sanofi Pasteur to build $500M vaccine manufacturing plant in Toronto
by Canadian Manufacturing.com Staff
The facility will produce antigens used in vaccines that guard against whooping cough, diphtheria and tetanus
TORONTO—French pharmaceutical company Sanofi Pasteur is greatly expanding its Canadian footprint with a $500 million investment in a new Ontario manufacturing plant.
The new facility will be sited at the company’s existing Toronto complex and represents one of Sanofi’s largest-ever investments in a single building.
Federal and provincial government officials, including Minister of Innovation, Science and Economic Development Navdeep Bains, joined Sanofi executives for the official announcement at the North York site April 12.
The facility will focus entirely on producing vaccines—particularly a five-component acellular pertussis antigen that’s seeing increased global demand. The site will also be set up to produce antigens used in diphtheria and tetanus vaccines.
The company expects to complete work on the new plant by 2021.
